主页
市场
图表与思路
Algo
新闻
Store
经纪商
下载
经济日历
交易信号
网页端
键入
/
进行搜索:@user,$symbol
查找
登录
创建账户
Deutsch
English
Русский
中文
Español
Português
日本語
한국어
Français
Italiano
Türkçe
NGNE
#2510
Neurogene, Inc. Common Stock
23.490
0
+21.87%
版块:
基础:
利润货币:
日范围
年范围
日变化
+21.87%
每月变动
+18.04%
6个月变化
-20.16%
年变化
-20.16%
前一天收盘价
19.275
0
Open
23.490
0
Bid
Ask
Low
23.490
0
High
23.490
0
交易量
39
市场
股票
医疗保健
NGNE
Open full chart
Financials
Overview
声明
Statistics
Dividends
Quarterly
Annual
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
TTM
Key stats
Total common shares outstanding
14.85 M
14.93 M
14.26 M
14.27 M
15.49 M
—
Valuation ratios
Enterprise value
556.67 M
204.7 M
96.24 M
154.55 M
197.43 M
652.93 M
Price to earnings ratio
-11.03
-5.34
-2.68
-3.46
-4.23
-15.71
Price to sales ratio
—
—
—
—
—
—
Price to cash flow ratio
6.2
5.69
3.05
3.9
4.52
17.16
Price to book ratio
0.62
1.29
0.24
0.28
0.3
2.12
Enterprise value to EBITDA ratio
—
—
—
—
—
—
Profitability ratios
Return on assets %
0.12
0.06
0.07
0.07
0.07
0.28
Return on equity %
0.15
0.06
0.08
0.08
0.08
0.3
Return on invested capital %
—
—
—
—
—
—
Gross margin %
—
—
—
—
—
—
Operating margin %
—
—
—
—
—
—
EBITDA margin %
—
—
—
—
—
—
Net margin %
—
—
—
—
—
—
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
9.09
20.84
21.03
18.07
18.39
78.33
Inventory turnover
—
—
—
—
—
—
Asset turnover
0
—
—
0
0
—
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
0.92
1
0.99
0.92
0.92
3.83
EBIT per share
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
Cash per share
8.2
17.78
13.94
13.04
12.54
57.3
Net current asset value per share
8.47
17.98
14.12
13.25
12.78
58.13
Tangible book value per share
8.11
17.67
13.9
12.98
12.54
57.09
Working capital per share
7.54
17.12
13.45
12.52
12.08
55.17
Book value per share
8.11
17.67
13.9
12.98
12.54
57.09
新闻
Netflix, Dell among market cap stock movers on Friday
Why Is Neurogene Stock Skyrocketing Friday? - Neurogene (NASDAQ:NGNE)
Neurogene-Aktie legt um 30 % zu nach ‚Breakthrough Therapy‘-Status der FDA
Neurogene stock surges 30% on FDA breakthrough therapy status
FDA grants breakthrough therapy status to Neurogene’s Rett drug
Neurogene: Stifel bekräftigt "Buy"-Rating und verweist auf solide Sicherheitsmarge
Stifel reiterates Buy rating on Neurogene stock, cites viable safety margin
Neurogene doses multiple patients in Rett syndrome gene therapy trial
Taysha Gene Therapies: Citizens bekräftigt "Market Outperform"-Rating
Citizens reiterates Market Outperform rating on Taysha Gene Therapies stock
Tracking Baker Brothers Portfolio – Q3 2025 Update (NASDAQ:INCY)
Neurogene: From Speculation To Execution With NGN-401 (NASDAQ:NGNE)